ACT News 222.83 06/26/2014 04:22:51 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 222.83 $ACT

Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - 2 mins ago
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.

World Market for Pain Management Drugs and Devices to 2017
M2 - 1 hr 48 mins ago
Research and Markets (http://www.researchandmarkets.com/research/xbzv4k/the_world_market) has announced the addition of the "The World Market for Pain Management Drugs and Devices" report to their offering. The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored. Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain. The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management. The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories: - Burn Pain - Cancer Pain - Dental/Facial Pain - Migraine Headache Pain - Musculoskeletal Pain - Neuropathic Pain - Obstetrical Pain - Pediatric Pain - Surgical and Trauma Pain This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented. As part of the study the following competitors are profiled: - Abbott Laboratories - Actavis, Inc (formerly Watson Pharmaceuticals, Inc.) - AstraZeneca plc. - Baxter International, Inc. - BioDelivery Sciences International (BDSI) - Boehringer Ingelheim - Boston Scientific - Bristol-Myers Squibb Company - DepoMed - DURECT Corporation - Eli Lilly & Co. - Endo Health Solutions Inc - GlaxoSmithKline plc - Grunenthal Group - Medtronic, Inc. - Merck & Co. - Novartis - Pain Therapeutics, Inc - Pfizer, Inc - Purdue Pharma - QRx Pharma - Sanofi - St. Jude Medical, Inc - TEVA Pharmaceuticals Industries, Ltd - The Medicines Company - Valeant Pharmaceuticals International, Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/xb...rld_market

Endo International to Expand Generics Business with DAVA Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 2:20PM CDT
Endo (ENDP) has inked a deal to buy DAVA Pharmaceuticals for a cash consideration of approximately $575 million.

Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
at The Street - Wed Jun 25, 9:34AM CDT
These heavily shorted stocks could get squeezed on any positive catalyst.

Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:

Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.

Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why.  VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...

Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline" . The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee.

Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...

3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Unusual Social Activity Today Around Actavis (ACT)
at The Street - Mon Jun 23, 10:41AM CDT
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate

Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -

Settlements, Statements, FDA Submissions and Approvals - Analyst Notes on Valeant, Pfizer, Actavis, Allergan and Teva
PR Newswire - Fri Jun 20, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Allergan, Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3940-100free.

Teva's Nuvigil Patent Infringement Lawsuits Resolved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 3:45PM CDT
Teva (TEVA) settled its patent infringement lawsuits for Nuvigil with Sandoz, Actavis (ACT), Lupin and Apotex.

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.

Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
PR Newswire - Thu Jun 19, 7:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon® Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal.

Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...

Stocks Open Mixed In Firm Trade; Adobe, FedEx, Air Products Jump
at Investor's Business Daily - Wed Jun 18, 9:33AM CDT
Stocks churned out a mixed open Wednesday as earnings reports fueled some significant early moves. The Nasdaq slipped 0.2%. The Dow Jones industrial average was down 0.1%. The S&P 500 hung on to a fractional gain. Investor attention on the stock...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 77

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 87

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Mile High Labs Moves CBD Isolate Into FDA DMF Pathway

Updated Category News Views 76

A Quiet Filing With Real Commercial Weight Cannabis headlines usually arrive wearing a clown suit; this one showed up with paperwork. Mile High Labs says it filed Type II Drug Master File No. 044151 with the U.S. Food and Drug Administration for a 98% CBD isolate on October 2, 2026. That is not a product approval, not permission to market a CBD drug, and certainly not a...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 67

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 144

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 122

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 63

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia Corporation Reports Managerial Transaction Details

Updated Category News Views 170

Nokia Corporation’s Managerial Transaction Insights Nokia Corporation has been making headlines recently as it showcases the ongoing engagement of its management in company affairs. An important transaction notification concerning Nishant Batra, a senior manager at Nokia, has been released, highlighting the movement of shares within the company. Transaction Overview...

Continue Reading
RBI Urges Banks to Limit Short Selling as Rupee Dips

Updated Category News Views 121

RBI's Call to Support the Rupee Amidst Market Challenges The Reserve Bank of India (RBI) has recently taken proactive measures to address the vulnerabilities of the Indian rupee, which has been hovering close to unprecedented low levels. This action follows a period in which market fluctuations have raised concerns among financial circles, particularly regarding the...

Continue Reading
Workhorse Group's E-GEN Platform Achieves Major Milestone

Updated Category News Views 260

Revolutionizing Commercial Transportation with E-GEN Milestone Workhorse Group Inc., renowned for its pioneering electric vehicle solutions, achieved an incredible feat with its E-GEN vehicles recently surpassing a remarkable 10 million cumulative miles. This significant milestone not only validates the platform’s durability but also showcases its reliability in...

Continue Reading
Investors Urged to Act Ahead of Starbucks Class Action Deadline

Updated Category News Views 231

Important Deadline for Starbucks Corporation Investors In light of recent developments, investors who purchased securities of Starbucks Corporation (NASDAQ: SBUX) are being encouraged to take action before an important deadline. Rosen Law Firm, a well-respected global investor rights law firm, has issued reminders for these investors. They are informing those who bought...

Continue Reading
Effective Strategies to Enhance Your Credit Before Holidays

Updated Category News Views 78

Essential Strategies for Boosting Your Credit Score TomoCredit, a dedicated platform aiding immigrants and underserved communities in accessing crucial credit without relying on credit scores, has developed a practical 5-week plan to help consumers enhance their credit before the holiday shopping frenzy. This guide aims to empower individuals to take control of their...

Continue Reading